Emergent BioSolutions Secures $64.5M Contract for Botulism Antitoxin to Bolster U.S. Biodefense
EBS sits 67% above its 52-week low of $5.615.
Summary
Emergent BioSolutions secured a $64.5 million contract modification for its Bat® botulism antitoxin, supporting the U.S. biodefense strategy. This is a significant revenue boost for the company, which has a market cap of approximately $473 million. The contract reinforces Emergent's critical role in national security and follows other recent government contracts, including over $60 million for smallpox countermeasures announced in March.
At the time of this announcement, EBS was trading at $9.35 on NYSE in the Life Sciences sector, with a market capitalization of approximately $473.7M. The 52-week trading range was $5.62 to $14.06. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.